Rosen Law Firm, a global investor rights law firm, reminds purchasers of ADMA Biologics, Inc. (NASDAQ: ADMA) securities between March 27, 2024 and March 25, 2025, inclusive, of the important June 30, 2026 lead plaintiff deadline in the securities class action first filed by the firm.
The lawsuit alleges that ADMA Biologics made false and/or misleading statements and/or failed to disclose that: (1) the company's financial results were inflated due to improper revenue recognition; (2) the company lacked adequate internal controls over financial reporting; and (3) as a result, defendants' statements about its business, operations, and prospects were materially false and misleading at all relevant times.
Investors who purchased ADMA securities during the class period may be eligible to serve as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. The deadline to file a motion to serve as lead plaintiff is June 30, 2026.
Rosen Law Firm has extensive experience in securities class actions and has recovered hundreds of millions of dollars for investors. The firm encourages investors to contact them for more information about their rights.
